Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP)

ConclusionsRaltegravir 400  mg+lamivudine 150 mg showed high levels ofex vivo HIV protection, associated with high drug concentrations persisting after discontinuation in vaginal and rectal compartments, supporting further investigation of these agents for PrEP.
Source: Journal of Antimicrobial Chemotherapy - Category: Microbiology Source Type: research